Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response

Area of Science:

• Immunology
• Cancer Biology
• Molecular Medicine

Background:

• Tumor cells evade immune surveillance by inducing dysfunction in dendritic cells (DCs).
• Intracellular mediators of DC dysfunction are poorly understood, limiting effective cancer immunotherapies.
• Targeting DC dysfunction is crucial for developing potent anti-tumor immune responses.

Purpose of the Study:

• To identify key intracellular mediators regulating DC dysfunction within the tumor microenvironment.
• To investigate the role of MAPK-activated protein kinase 2 (MK2) in maintaining a suppressive DC phenotype.
• To evaluate the therapeutic potential of targeting MK2 for DC-centered cancer immunotherapy.

Main Methods:

• Utilized a cell type-specific murine knock-out model targeting MK2 in CD11c+ cells.
• Analyzed DC populations and phenotype within the melanoma tumor microenvironment.
• Assessed CD8+ T cell responses and tumor elimination following toll-like receptor (TLR) activation with tumor antigen.

Main Results:

• MK2 deletion in CD11c+ cells resulted in an expansion of stimulatory CD103+ DCs.
• This led to a potent CD8+ T cell response and elimination of aggressive B16-F10 tumors upon TLR activation.
• Tumor infiltration by suppressive myeloid cells was significantly reduced.

Conclusions:

• MK2 is a critical regulator maintaining DC suppressive function in the melanoma tumor microenvironment.
• Inhibiting MK2 promotes DC activation and enhances anti-tumor CD8+ T cell responses.
• MK2 represents a targetable pathway for developing novel DC-centered immunomodulatory cancer therapies.